NCT04958109

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

The goal of this study is to understand how exogenous kisspeptin affects metabolism by evaluating responses to an oral glucose tolerance test

Detailed description

Assignment: Each study subject will serve as their own control. The order of the visits will be randomized. Delivery of Interventions: * Prior to the study visit, subjects will undergo a review of their medical history and screening laboratories. * During the inpatient study, the subjects will * Undergo a 16-hour kisspeptin infusion * Undergo an oral glucose tolerance test

Conditions

• Metabolic Diseases

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Oral Glucose Tolerance Test	Administration of a 75 gm oral glucose tolerance test
DRUG	Kisspeptin	Intravenous administration of kisspeptin 112-121 x 16 hours
DRUG	Placebo	Intravenous administration of Placebo 16 hours

Timeline

• Start date: 2021-10-28
• Primary completion: 2022-10-31
• Completion: 2022-10-31
• First posted: 2021-07-12
• Last updated: 2026-03-06
• Results posted: 2024-12-12

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study